Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.
The lead Eikon drug, EIK1001, is a small molecule designed to hit toll-like receptors 7 and 8 (TLR7/8). Activating these receptors is intended to spark an immune response that fights cancer.
However, Mounjaro belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Kidney problems have been ...
Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D ...
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...
Toll-like receptor. Toll-like receptors (TLRs) are one of the largest and best-studied families of pattern-recognition receptors of the innate immune system. TLRs recognize pathogen- and danger ...
STING/TLR-agonist Antibody-Drug Conjugates and mRNA technologies You will also have the opportunity to ask any burning questions and go back to your teams with a full picture of the innate ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Beijing Synthetic Vaccine Biosciences Co. Ltd. has synthesized Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of autoimmune disease, cancer, inflammatory disorders and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results